Cargando…

Study to increase the pneumococcal vaccination rates of individuals aged 65 years and older

BACKGROUND: In our study, we intended to observe the impact of recommending the pneumococcal vaccine to individuals who were called on the phone or interviewed face-to-face by their doctors on vaccination rates. METHODS: Two hundred individuals who were 65 years old and older were included in our st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biyik, M. V., Arslan, I., Yengil Taci, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576541/ https://www.ncbi.nlm.nih.gov/pubmed/32985407 http://dx.doi.org/10.1017/S1463423620000389

Ejemplares similares

The Evaluation of Frailty in the Elderly and Affecting Biopsychosocial Factors: A Cross-Sectional Observational Study
por: Taci, Duygu Yengil, et al.
Publicado: (2023)

Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective
por: Earle, Kylie, et al.
Publicado: (2016)

Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality
por: Thomas, Roger E.
Publicado: (2021)

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
por: Nielsen, Katrine Finderup, et al.
Publicado: (2022)

Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice
por: Frank, Oliver, et al.
Publicado: (2020)

1173. Risk of Pneumococcal Disease and Rate of Pneumococcal Vaccination Among Medicare Beneficiaries Aged 65 Years and Older Residing in Long-Term Care Facilities — United States, September 1, 2014 – December 31, 2019
por: Kobyashi, Miwako, et al.
Publicado: (2023)

744. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine and Influenza Vaccine Against Pneumococcal Pneumonia Among Elderly Patients Aged 65 Years and Older in the Republic of Korea: A Case–Control Study
por: Kim, Jong Hun, et al.
Publicado: (2018)

Improving population health in resident clinics: increasing pneumonia vaccination rates in adults 65 years and older
por: McGreevy, Sheila, et al.
Publicado: (2020)

1436. Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation
por: Almendares, Olivia M, et al.
Publicado: (2018)

596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older
por: Pilishvili, Tamara, et al.
Publicado: (2014)

1797. Pneumococcal Vaccination in Veterans 65 years and older with Pneumococcus in the Veterans Health Administration (VHA) since November 2021
por: Schirmer, Patricia, et al.
Publicado: (2023)

151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old
por: Pilishvili, Tamara, et al.
Publicado: (2018)

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004
por: Mooney, John D, et al.
Publicado: (2008)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
por: Tomczyk, Sara, et al.
Publicado: (2014)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
por: Matanock, Almea, et al.
Publicado: (2019)

Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
por: Black, Carla L., et al.
Publicado: (2017)

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
por: Marbaix, Sophie, et al.
Publicado: (2018)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
por: van Hoek, Albert Jan, et al.
Publicado: (2016)

Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany
por: Deb, Arijita, et al.
Publicado: (2022)

Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy
por: Astengo, Matteo, et al.
Publicado: (2021)

The second study of infectious intestinal disease (IID2): increased rates of recurrent diarrhoea in individuals aged 65 years and above
por: Tam, Clarence C, et al.
Publicado: (2013)

Is asthma in the elderly different? Functional and clinical characteristics of asthma in individuals aged 65 years and older
por: Curto, Elena, et al.
Publicado: (2019)

A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician’s attitude
por: Nakamura, Atsushi, et al.
Publicado: (2020)

Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review
por: Addario, Alexandra, et al.
Publicado: (2023)

2205. Clinical Burden of Pneumococcal Disease in US Adults Aged 65 Years and Above with Chronic or Immunocompromising Conditions
por: Deb, Arijita, et al.
Publicado: (2019)

Use of 13-valent pneumococcal conjugate vaccine in children older than 5 years of age
por: Principi, Nicola, et al.
Publicado: (2014)

Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older
por: Pillsbury, Alexis J., et al.
Publicado: (2020)

Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age
por: Chan, Melissa V., et al.
Publicado: (2020)

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
por: Asai, Nobuhiro, et al.
Publicado: (2021)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older
por: Wong, Hui-Lee, et al.
Publicado: (2023)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
por: van den Biggelaar, Anita H. J., et al.
Publicado: (2017)

1730. Increasing Vaccination Rates of 23-valent Pneumococcal Polysaccharide Vaccine Among Patients at High-Risk for Invasive Pneumococcal Disease
por: Lyon, Edward, et al.
Publicado: (2023)

A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
por: Hamaguchi, Megumi, et al.
Publicado: (2023)

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales
por: Djennad, Abdelmajid, et al.
Publicado: (2019)

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
por: Vila-Corcoles, Angel, et al.
Publicado: (2010)

Gender and Age Differences in Anthropometric Characteristics of Taiwanese Older Adults Aged 65 Years and Older
por: Su, Yan-Jhu, et al.
Publicado: (2023)

2713. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine in Korean National Population Cohort over 65 Years Old
por: Sohn, Sangho, et al.
Publicado: (2019)

Optimal age targeting for pneumococcal vaccination in older adults; a modelling study
por: Thindwa, Deus, et al.
Publicado: (2023)

Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up
por: Vila-Córcoles, Angel, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1e8m82dg2c3ej8l6bcli53tdr6